Mirum Pharmaceuticals Inc. Common Stock (MIRM)

About MIRM

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the Unite…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

433

Website

mirumpharma.com/

Fundamentals

1-day range

$96.55$100.06

Market cap

$6.38B

P/E (trailing)

—

P/E (forward)

-281.13

EPS (trailing)

$-14.55

Dividend yield

—

Beta

0.60

Avg. volume

804.2K

Forecasts

14 analyst ratings

Mirum Pharmaceuticals Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• MIRM

  Mirum Pharmaceuticals Inc. Common Stock

  $97.44

  ▼ 2.32%
  Market cap $6.38BP/E —
  $63.23$130
• COGT

  Cogent Biosciences Inc. Common Stock

  $34.68

  ▼ 6.50%
  Market cap $6.64BP/E —
  $11.6$43.73
• ERAS

  Erasca Inc. Common Stock

  $18.03

  ▼ 7.49%
  Market cap $6.11BP/E —
  $1.33$24.28
• BLTE

  Belite Bio Inc American Depositary Shares

  $151.65

  ▼ 3.42%
  Market cap $6.09BP/E —
  $62.18$200
• LGND

  Ligand Pharmaceuticals Incorporated Common Stock

  $280

  ▼ 1.59%
  Market cap $5.85BP/E 38.07
  $158.4$326.63
• DNTH

  Dianthus Therapeutics Inc. Common Stock

  $105.72

  ▼ 5.22%
  Market cap $5.80BP/E —
  $22.81$117.88
• KNSA

  Kiniksa Pharmaceuticals International plc Class A Ordinary Shares

  $78.1

  ▼ 2.13%
  Market cap $5.73BP/E 75.29
  $33.25$82.94

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Citizens Reiterates Market Outperform on Mirum Pharmaceuticals, Maintains $137 Price Target
  benzinga · 8/27/2026
• X4 Pharmaceuticals: Making Progress, But The Market Is Ahead Of The Trial (Rating Downgrade)
  SeekingAlpha · 8/19/2026
• TD Cowen Maintains Buy on Mirum Pharmaceuticals, Lowers Price Target to $140
  Benzinga · 8/6/2026
• RBC Capital Maintains Outperform on Mirum Pharmaceuticals, Lowers Price Target to $135
  Benzinga · 8/6/2026
• Citizens Maintains Market Outperform on Mirum Pharmaceuticals, Lowers Price Target to $137
  Benzinga · 8/6/2026
• HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Lowers Price Target to $140
  Benzinga · 8/6/2026
• Mirum Pharmaceuticals, Inc. (MIRM) Q2 2026 Earnings Call Transcript
  SeekingAlpha · 8/5/2026
• Mirum Pharmaceuticals (NASDAQ:MIRM) Slides on Wider Loss and Volixibat Delay Despite Revenue Beat
  ChartMill · 8/5/2026
• Wondering what's happening in today's after-hours session?
  ChartMill · 8/5/2026

• Eric Bjerkholt · August 11, 2026 · Sale

  6.0K @ $99.9
• Christopher Peetz · August 10, 2026 · Option Exercise

  20.0K @ $2.94
• Christopher Peetz · August 10, 2026 · Sale

  2.3K @ $100.14
• Christopher Peetz · August 10, 2026 · Sale

  6.0K @ $99.25
• Christopher Peetz · August 10, 2026 · Sale

  11.7K @ $98.51
• Howe Jolanda · August 3, 2026 · Sale

  1.8K @ $105.29
• Christopher Peetz · July 6, 2026 · Option Exercise

  20.0K @ $2.94
• Christopher Peetz · July 6, 2026 · Sale

  1.7K @ $124.79
• Christopher Peetz · July 6, 2026 · Sale

  2.0K @ $123.74
• Christopher Peetz · July 6, 2026 · Sale

  4.2K @ $122.34
• Christopher Peetz · July 6, 2026 · Sale

  12.1K @ $121.65
• Eric Bjerkholt · July 6, 2026 · Sale

  300 @ $124.94
• Eric Bjerkholt · July 6, 2026 · Sale

  528 @ $123.84
• Eric Bjerkholt · July 6, 2026 · Sale

  1.0K @ $122.43
• Eric Bjerkholt · July 6, 2026 · Sale

  3.1K @ $121.67

Institutional Ownership

March 31, 2026

Total shares held

66.48M

Total value held

$5.89B

Institutional holders

304